Mupirocine Viatris (Mupirocin)

Mupirocin inhibits bacterial isoleucyl‑tRNA synthetase, an enzyme essential for incorporating isoleucine into proteins. This blockade stops bacterial protein synthesis, resulting in a bacteriostatic effect at low concentrations and a bactericidal effect at higher concentrations, primarily targeting Staphylococcus aureus and Streptococcus pyogenes.

The dosing regimen is set by the prescribing clinician based on infection type, severity, patient age and weight. Typically a thin layer is applied to the affected area one to three times daily for the prescribed duration. Patients should follow the exact instructions on the label and from their healthcare provider.

The pregnancy category for mupirocin is not definitively established. It should be used during pregnancy or lactation only if the potential benefit justifies any potential risk to the fetus or infant, and after consultation with a healthcare professional. Topical use generally results in minimal systemic absorption.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with agents such as bacitracin or fusidic acid, mupirocin offers a broader spectrum against methicillin‑resistant Staphylococcus aureus (MRSA) and a lower propensity for resistance development. It is generally more expensive and is best reserved for infections where its specific activity is required.

Store the product at room temperature, below 25 °C, in the original tube or container. Keep it away from excessive heat, moisture and direct sunlight. Ensure the cap is tightly closed to maintain stability and potency throughout its shelf life.

The medication is applied topically to clean, dry skin. A thin layer should be spread over the affected area, usually one to three times per day, as directed by a healthcare professional. Hands should be washed before and after application, and the treated area should be covered with a sterile dressing only if advised.

Although rare, serious adverse reactions can include allergic contact dermatitis, Stevens‑Johnson syndrome, toxic epidermal necrolysis, and systemic effects such as neutropenia from excessive absorption. Patients should discontinue use and seek immediate medical attention if they develop widespread rash, blistering, fever, or signs of an allergic reaction.

Individuals with a known hypersensitivity to mupirocin or any component of the formulation should avoid the product. It is also contraindicated for use on large body surfaces or for prolonged periods without medical supervision, and should not be applied to the eyes, ears or mucous membranes. Pregnant or lactating women should only use it if prescribed after risk‑benefit assessment.